Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II)

Abstract

Abstract. the new enzyme-targeting radiosensitization treatment, kochi Oxydol-radiation therapy for unresectable carcinomas, type ii (kOrtuc ii), markedly enhances the radiotherapeutic effect of treatment for various types of locally advanced malignant neoplasms. patients who had declined surgical treatment and systemic chemotherapy, as well as a total of 14 stage i breast cancer patients, were enrolled. a maximum of 6 ml of kOrtuc ii was injected into tumor tissue twice a week under ultrasonographic guidance, immediately prior to each administration of radiation therapy. the median observation period was 21.6 months with a range of 4-48 months, and the therapy was well tolerated. contrast-enhanced magnetic resonance imaging and [18 F]-fluorodeoxyglucose positron emission computed tomography revealed that all primary breast tumors completely responded, and none of the subjects experienced local recurrence during the observation period. ultrasonography depicted tumor-like findings in 2/14 cases after therapy. The intratumoral flow signal on color-Doppler sonography was positive in 4/14 cases before therapy, and the signal disappeared from all cases after therapy. The absence of a flow signal after therapy suggested that the tumor-like findings on ultrasonography were from scar tissue. Excellent local control based on accurate radiological evaluation implies that kOrtuc ii has the potential to replace surgery as a therapeutic option for stage i breast cancer. precise evaluation by various radiological modalities helped to gage the success of this therapy. IntroductionBreast conserving surgery has become the most popular surgical procedure for primary breast cancer (1). The significance of extended resection has become less important, since the long-term survival rate among women who undergo breastconserving surgery is the same as that among women who undergo radical mastectomy (2). thus, nowadays, local control is expected to be minimally invasive on the basis that permanent curability is estimated to be comparable. Various types of non-surgical ablation have been introduced as a local control for early breast cancer that also achieve cosmetic gains (3-7). a new enzyme-targeting radiosensitization treatment containing hydrogen peroxide and sodium hyaluronate for percutaneous injection, kochi Oxydol-radiation therapy for unresectable carcinomas, type ii (kOrtuc ii) (8), was recently developed. it markedly enhances the radiotherapeutic effect of treatment for various types of tumors that are not superficially exposed, such as breast cancer and other types of soft tissue tumors (8). As precise assessment of therapeutic efficacy by radiological imaging is essential for the success of kOrtuc ii, contrast enhanced breast magnetic resonance imaging (cE-breast mri), ultrasonography (uS) and [18 F]-fluorodeoxyglucose positron emission computed tomography (FdG-pEt-ct) were employed to assess therapeutic outcomes. the aim of the present study was to report the therapeutic outcome of kOrtuc ii for stage i breast cancer precis...

Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane

“…Though the numbers of the patients treated with KORTUC II in the individual studies are small, good therapeutic effects of KORTUC II have also been reported in other studies (1–8). Therefore, KORTUC II may be a novel therapeutic treatment for patients with breast cancer (3,4,6,8). KORTUC II consists of sodium hyaluronate 0.83% w/v and hydrogen peroxide 0.5% w/v, which are inexpensive and readily available.…”

Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II, in patients with stage I primary breast cancer

“…1 (18–20). Through the use of KORTUC II, hypoxic and radioresistant cancer cells become hyperoxic and radiosensitive, with demonstrable therapeutic effects (16–26). In our previous studies, the effectiveness of KORTUC II for the treatment of supraclavicular lymph node metastases, recurrent breast cancer and stage IV primary breast cancer was demonstrated (18–20).…”

Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging

“…Furthermore, cCR was also confirmed through other diagnostic modalities performed during the follow-up period. Actually, the therapeutic effect was evaluated by PET-CT [ 10 ], breast MRI, ultrasonographic examination [ 11 ], and mammography [ 12 ] at approximately 4 months and approximately 10 months after KORTUC II, and these examinations were repeated biannually for at least 5 years after KORTUC II treatment, thereafter. Only one patient (case 5 in Table 1 , Table 2 and Table 3 ) had local recurrence, which was discovered at 39 months; this patient died after 83 months of KORTUC II.…”